Kidney Disease

Drug Halves Risk of Kidney Transplant Rejection

Oxford University scientists in the UK have shown that a powerful drug given at the time of a kidney transplant operation not only halves the early risk of rejection, but that it also allows a less toxic regimen of anti-rejection drugs to be used after the operation.

The key results wre published in July 2014 The Lancet and presented at the World Transplant Congress in San Francisco on July 27th. They will help doctors faced with a difficult transplant conundrum: the powerful combinations of treatments used to prevent early kidney rejection may cause kidney damage later and may subsequently be a cause of transplant failure.

A release from the university explains that one of the main culprits is a class of drugs known as calcineurin inhibitors. These drugs are very effective at preventing rejection in the first weeks and months after a transplant, but their lasting effects can have serious consequences for the kidney later on.

Kidney transplantation is still the best treatment for patients with kidney failure, but much more subtle approaches are needed if success rates are to be improved.

Around 15,000 people undergo transplant in the USA every year and 2,000 in the UK. Patients need to take drugs to suppress their immune system in order to reduce the chances that it will reject the new kidney. It is a risky procedure since disabling the immune system in this way can lead to an increased number of infections and cancer.

The 3C study (Campath, Calcineurin inhibitor reduction and Chronic allograft nephropathy) tested whether alemtuzumab (Campath; an anti-rejection treatment) partnered with low dose tacrolimus (a calcineurin inhibitor) could reduce transplant rejection when compared with existing treatment.

The study recruited 852 patients who underwent kidney transplantation in the UK between 2010 and 2013.

The release quotes chief Investigator Professor Peter Friend as saying, “Our primary aim was to find out whether alemtuzumab-based induction therapy would produce worthwhile reductions in acute rejection, but we also wanted to see whether we could use it with a lower dose of tacrolimus, because there is some evidence that tacrolimus contributes to long-term transplant failure.”

Among those allocated alemtuzumab-based induction therapy, 7.3% experienced acute rejection compared to 16.0% of those allocated basiliximab-based induction therapy – a halving in the risk of early rejection.
‘These are important findings which we hope will guide treatments in the future,’ said Professor Friend.

Although alemtuzumab has been available for many years, its use has been limited by concerns about possible side effects, in particular infections.

But no overall excess in serious side effects – such as infections and cancer – was found in patients on the treatment, the scientists report.

Medical Research Council-funded researcher, Dr Richard Haynes of the Clinical Trial Service Unit at Oxford University, said: “The safety data from the 3C Study are reassuring. There was no overall excess risk of infections or other known complications of immunosuppression.”

Medical Research Council scientist Professor Colin Baigent, one of the other lead investigators, said: “These results from the first 6 months of the 3C Study demonstrate the importance of large randomized trials in transplantation. The planned long-term follow-up of the 3C Study will provide a unique opportunity to investigate whether these differences in short-term outcomes translate into improvements in the long-term which will be of great interest to patients and their doctors.”

Dr. Richard Haynes expressed his gratitude to all of the participants in the study: “Without their help we would not have been able to make this progress towards improving the care of people who receive kidney transplants,” he said.

Prof. James Neuberger, Associate Medical Director at NHS Blood and Transplant, said: “NHS Blood and Transplant is delighted to be supporting this multi-centre UK study into the immunosuppression treatment of patients who have received a kidney transplant. We would like to congratulate the investigators on the good outcomes they are reporting and we hope these results will be sustained in the long term. Improving outcomes for patients and their families, will help us to achieve our aim to make every donation count and enable even more patients receive the transplants they need.”

you may also like

Recipes We

Khela88

Fancywin

Jita Ace

Betjili

https://betvisa1.org/

jeetbuzz লগইন

jeetwin app

baji999

winbuzz

betvisa login

winbuzz

six6s

babu88

marvelbet

krikya

mostplay

4rabet

leonbet

pin up

mostbet

all rummy app

Fastwin

Jitawin

R777

Bhaggo

PBC88

Winbdt

Crickex

Betjee

Glory Casino

Jita Bet

Melbet

Jwin7

Jita Ace

Krikya

Six6s

Betjili

Mostplay

Jeetbuzz

Jeetwin

Mostbet

Baji999

Marvelbet

Betvisa

Mcw

Nagad88

Babu88

Jaya9

babu88 babu88 jeetwin abbabet nagad88 marvelbet melbet mostbet six6s crickex mcw casino baji999 betvisa krikya mostplay crazy time jeetbuzz 79king1 good88 11bet xoso66 nohu78 xin88 nohu90 v9bet fastwin betvisa
jeetbuzz
babu88
babu888
jeetwin
nagad88
jaya9
khela88
mostplay
baji999
abbabet
1xbet 12bet marvel bet 91 club betvisa login baji999 sky247 gugobet lotus365 yolo247 bsport loto188 bsport site 8day xoso66 v9bet rummy deity yono rummy new88 typhu88 jeetbuzz dafabet lotus365 bet88 v9bet đăng nhập thienhabet 188bet link dafabet login betvisa king567 yolo247 login 1xbet login 24betting 91club crickex kubet new88 hi88 jun88 w88 shbet mksports 33win f8bet 123b fb88 vn88 mu88 five88 bk8 w388 gnbet mcw casino thienhabet sodo casino cmd368 bsport eubet sbobet mibet cmd368 Faridabad Satta Satta King 786 Dafabet betvisa yono rummy rummy apk

alo789

https://metalwave.com.mx/app/

https://meisetio.com/wp-includes/js/jquery/ai/index.php?tunnel=alo-789

https://purneauniversity.ac.in/assets/js/mk/?tunnel=baji999

fastwin

fastwin

winzo

winzo

futemax

Kèo nhà cái

bongdadzo

Tỷ số bóng đá

KQBD

Kết quả bóng đá

rummy nabob

hi88

8day

97win

n88

red88

king88

j88

i9bet

good88

nohu78

99ok

bet168

satta king

satta matta matka

Canais Play

ALO789

yono rummy
rummy deity
rummy nabob
rummy wealth
daman games
jeetbuzz
yolo247
baji999
rummy gold
188bet
v9bet
789bet
crickex
1xbet
thienhabet
c54
sky88
33win
79king
kubet
shbet
good88
3king
nohu
lucky88
97win
xoso66
xin88
daga88
yolo247
jeetbuzz
betvisa
jeetwin
baji999
nagad88
babu88
mostplay
babu888
jaya9
khela88
jaya9
khela88
jeetbuzz
betvisa
abbabet
babu88
babu888
jeetwin
nagad88
jaya9
joya 9
khela88
mostplay
marvelbet
baji999

Sponsored From Malaysia

말레이시아에서 후원